Sunnyvale, California-based BaseHealth has closed an $8.5 million Series C funding round, according to a news release.
The round includes $2.5 million from lead investor HBM Healthcare Investments. Other investors weren’t disclosed in the release.
Founded in 2011, BaseHealth takes an analytics-based approach to population health. Its predictive health platform gives organizations the information needed to identify patients at risk for 43 chronic diseases. Ultimately, the startup seeks to help health systems control the diseases of these “invisible patients” and save them from potential costly treatment in the future.
BaseHealth’s platform relies on peer-reviewed medical literature, as well as laboratory, family history, biometric, and behavioral data. The company also supplements it with ICD data and retrospective claims.
The Sunnyvale startup said it will use the latest investment to further develop its analytics system.
In a statement, BaseHealth CEO Jason Pyle commented on his company’s latest news:
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Healthcare systems have a lot of data and yet they still have a hard time finding these patients, making it hard to respond proactively to patient care needs. Our system enables healthcare professionals to assess the unknown risk that exists within their patient population and provide access and critical care needed to both improve our overall population’s health and improve the individual patient’s experience within the healthcare system.
Photo: TAW4, Getty Images
